InvestSMART

Nexalis Therapeutics Ltd (ASX:NX1)

ALERT: Price-sensitive ASX Announcement for NX1
Current share price for NX1 : $0.011 -0.014 (-56%)+
Release
26 May 2026 10:34AM
Price at Release
$0.025
Full Release
download
Summary
On 26 May 2026, Nexalis Therapeutics Ltd (ASX: NX1) announced the suspension of its securities from quotation under ASX Listing Rule 17.2. The suspension was initiated at the company's request, pending the release of an announcement regarding their existing debt funding facility. The voluntary suspension is intended to assist in managing continuous disclosure obligations. The company expects to release the relevant announcement by the start of normal trading on 28 May 2026. This decision has been approved by the board of Nexalis Therapeutics Ltd.
Key Points
  • Nexalis Therapeutics requested suspension from quotation
  • Suspension due to pending announcement on debt facility
  • Voluntary suspension intended for disclosure management
  • Expected announcement by 28 May 2026
  • Board approved the suspension request
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.